Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma, Barcelona, Spain.
Curr Opin Rheumatol. 2022 Jul 1;34(4):225-234. doi: 10.1097/BOR.0000000000000882. Epub 2022 Jun 9.
Psoriasis vulgaris is the commonest presentation of psoriatic disease, but morphologic variants such as pustular psoriasis (PP) and a closely related disease, pityriasis rubra pilaris (PRP), have been known for a long time, have been associated with rheumatologic manifestations indistinguishable from psoriatic arthritis (PsA) that may go unrecognized, and often represent a therapeutic conundrum. There is recent evidence that underlying genetic and pathogenetic differences may provide the basis for newer therapeutic approaches.
This narrative review highlights the clinical, genetic and pathogenetic characteristics of PP and PRP, their association with PsA and recent developments in their treatment, especially with biologic agents targeting IL-36 and other cytokines of pathogenic relevance.
The clinical manifestations of PP and PRP are less well known to rheumatologists than those of psoriasis, and recent advances in our insight on their pathogenesis may eventually overcome the therapeutic difficulties faced by dermatologists and rheumatologists in the management of these diseases and their rheumatologic manifestations.
寻常型银屑病是最常见的银屑病表现,但脓疱型银屑病(PP)和一种密切相关的疾病,毛发红糠疹(PRP),长期以来一直为人们所熟知,与银屑病关节炎(PsA)的风湿表现难以区分,可能被忽视,而且通常代表着治疗上的难题。最近有证据表明,潜在的遗传和发病机制差异可能为新的治疗方法提供基础。
本叙述性综述强调了 PP 和 PRP 的临床、遗传和发病机制特征,它们与 PsA 的关联以及最近在治疗方面的进展,特别是针对 IL-36 和其他致病相关细胞因子的生物制剂。
PP 和 PRP 的临床表现对风湿病学家来说不如银屑病那么为人所知,而我们对其发病机制的最新认识最终可能克服皮肤科医生和风湿病学家在治疗这些疾病及其风湿表现方面所面临的治疗困难。